GlassScriptPhysician profile
Jeffrey D Rind
NPI 1740282375
$26,566.22
in general payments reported to CMS, 2019-2025
79 companies · $5,509 in 2025
The $5,509 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,257 · 2020: $1,471 · 2021: $2,384 · 2022: $3,546 · 2023: $4,563 · 2024: $5,837 · 2025: $5,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,730.06 |
| Education | $178.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,861.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $3,433.55 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Lundbeck LLC | $1,652.47 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $898.69 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $886.33 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $783.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $698.49 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $653.89 | 2019-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $649.51 | 2019-2022 | |
| Amgen INC. | $612.00 | 2019-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $566.96 | 2019-2025 | Nuplazid, Daybue |
| Lilly USA, LLC | $560.27 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Emd Serono, INC. | $548.69 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $491.59 | 2022-2025 | Rytary, Crexont, Ongentys |
| Mdd US Operations, LLC | $484.25 | 2019-2025 | Apokyn, Gocovri, Apokyn |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.